STAT1 and melanoma: Bufalin disrupts the ATP1A1-Cav-1 complex, reversing drug resistance in melanoma (63), while cardiac glycosides inhibit STAT1-mediated IDO1 expression (60), demonstrating synergy with immune checkpoint inhibitors.